Compare Raymond James Financial, Inc. (RJF) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Tempus AI — how do they compare? Raymond James Financial, Inc. trades at $158.14 (market cap $30.25B), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Raymond James Financial, Inc. is far larger — about 2.4× Tempus AI's market cap, and Raymond James Financial, Inc. pays a 1.37% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 74 Days and Tempus AI for 22 Days on average.
| RJF | TEM | |
|---|---|---|
Market Cap | $30.25B | $12.58B |
Volume | 1,288,635 | 7,444,569 |
Sector | Financials | Broad Market / Factor |
52-Week High | $181.18 | $99.28 |
52-Week Low | $140.89 | $41.55 |
Typical Hold Time | 74 Days | 22 Days |
Enterprise Value | $24.12B | $13.21B |
Dividend Yield | 1.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $158.6, down 0.58% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.14, and maintains solid fundamentals including a P/E of 13.71 and ROE of 18.48%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical weakness and high investing cash outflows pose risks. Revenue growth and margin stability support long-term value, though market volatility and expense pressures remain concerns for investors.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
